scispace - formally typeset
Open AccessJournal ArticleDOI

MiR-148a, a microRNA upregulated in the WNT subgroup tumors, inhibits invasion and tumorigenic potential of medulloblastoma cells by targeting Neuropilin 1.

Reads0
Chats0
TLDR
expression of miR-148a to levels comparable to that in the WNT subgroup tumors was found to inhibit proliferation, clonogenic potential, invasion potential and tumorigenicity of medulloblastoma cells.
Abstract
Medulloblastoma, a common pediatric malignant brain tumor consists of four molecular subgroups viz. WNT, SHH, Group 3 and Group 4. MiR-148a is over-expressed in the WNT subgroup tumors, which have the lowest incidence of metastasis and excellent survival among all medulloblastomas. MiR-148a was expressed either in a transient manner using a synthetic mimic or in a stable doxycycline inducible manner using a lentiviral vector in non-WNT medulloblastoma cell lines. Expression of miR-148a to levels comparable to that in the WNT subgroup tumors was found to inhibit proliferation, clonogenic potential, invasion potential and tumorigenicity of medulloblastoma cells. MiR-148a expression in medulloblastoma cells brought about reduction in the expression of NRP1, a novel miR-148a target. Restoration of NRP1 expression in medulloblastoma cells was found to rescue the reduction in the invasion potential and tumorigenicity brought about by miR-148a expression. NRP1 is known to play role in multiple signaling pathways that promote tumor growth, invasion and metastasis. NRP1 expression in medulloblastomas was found to be associated with poor survival, with little or no expression in majority of the WNT tumors. The tumor suppressive effect of miR-148a expression accompanied by the down-regulation of NRP1 makes miR-148a an attractive therapeutic agent for the treatment of medulloblastomas.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer.

TL;DR: It is found that lower expression of miR-148a is detected in higher-grade tumor samples and correlated with increased likelihood to develop metastases and poor prognosis in subsets of breast cancer patients, particularly those with TNBC.
Journal ArticleDOI

Neuropilins in the Context of Tumor Vasculature

TL;DR: This review highlights the diverse neuropilin ligands and interacting partners on endothelial cells, which are relevant in the context of the tumor vasculature and the tumor microenvironment.
Journal ArticleDOI

Stimulation of medulloblastoma stem cells differentiation by a peptidomimetic targeting neuropilin-1.

TL;DR: The results highlighted that targeting NRP-1 with MR438 could be a potential new strategy to differentiate MB stem cells and could limit medulloblastoma progression.
Book ChapterDOI

Neuropilin: Handyman and Power Broker in the Tumor Microenvironment.

TL;DR: The suitability of various neuropilin-targeting substances and the intervention in neuropILin-mediated interactions is considered as a possible building block of tumor therapy.
Journal ArticleDOI

miR-148a suppresses human renal cell carcinoma malignancy by targeting AKT2

TL;DR: It is shown that miR-148a was significantly downregulated in RCC tissues and cell lines and AKT2 was confirmed to be a direct target of miR -148a, and mechanistic investigations showed thatmiR- 148a exerted its antitumor activity via inhibition of the AKT pathway in vitro and in vivo.
References
More filters
Journal ArticleDOI

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

TL;DR: A tetrazolium salt has been used to develop a quantitative colorimetric assay for mammalian cell survival and proliferation and is used to measure proliferative lymphokines, mitogen stimulations and complement-mediated lysis.
Journal ArticleDOI

miR-34 - a microRNA replacement therapy is headed to the clinic.

TL;DR: This review focuses on the molecular mechanisms of miR-34-mediated tumor suppression, pharmacologies in animal models of cancer, and a status update of a mi R-34 therapy that may be among the first miRNA mimics to reach the clinic.
Related Papers (5)